BioPharmSignal logoBioPharmSignal

Biotech News

Delcath Systems to Participate at the Society of Interventional Radiology 2026 Meeting

Delcath Systems (DCTH)Delcath SystemsCompany update

QUEENSBURY, N.Y. --(BUSINESS WIRE)--Apr. 1, 2026-- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, will attend the Society of Interventional Radiology (SIR) 2026 Annual Scientific Meeting, taking place

Open original release

Related news

DCTHDelcath Systems2026-05-12 12:00 EST

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

DCTHDelcath Systems2026-05-26 20:01 EST

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

REPLReplimune Group2026-05-31 12:00 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

REPLReplimune Group2026-05-30 12:00 EST

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

ATRCAtriCure2026-05-27 12:00 EST

AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference

BNTXBioNTech2026-05-22 09:00 EST

BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting

GERNGeron2026-06-01 12:00 EST

Geron to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

KYMRKymera2026-05-27 11:00 EST

Kymera Therapeutics to Participate in Fireside Chat at the Jefferies Global Healthcare Conference

ZNTLZentalis2026-05-13 20:05 EST

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

BMYBMYBristol-Myers Squibb Company2026-07-20 10:59 EST

Bristol Myers Squibb to Build the Most Powerful AI Factory in Life Sciences with NVIDIA

View all latest news

Delcath Systems

Delcath Systems is a medical device and specialty oncology company focused on liver-directed cancer treatment. Its platform is built around regional therapy delivery for difficult tumors.

Recent company news

DCTHDelcath Systems2026-05-26 20:01 EST

Delcath Systems Announces Two ASCO 2026 Investigator Initiated Trials-in-Progress Abstracts

DCTHDelcath Systems2026-05-12 12:00 EST

Delcath Systems to Participate at the H.C. Wainwright 4th Annual BioConnect Investor Conference

DCTHDelcath Systems2026-05-07 12:00 EST

Delcath Systems Reports First Quarter 2026 Results and Business Highlights

DCTHDelcath Systems2026-05-07 11:00 EST

Delcath Systems Announces Presentation of New Data on Percutaneous Hepatic Perfusion with Melphalan in Liver-Dominant Metastatic Breast Cancer at ESMO Breast Cancer 2026

DCTHDelcath Systems2026-04-23 12:30 EST

Delcath Systems to Host First Quarter 2026 Earnings Call

Stock data

Close
11.94 USD
Market cap
363.51M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States